272 related articles for article (PubMed ID: 33580780)
1. Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study.
Hussain A; Sun C; Selvin E; Nambi V; Coresh J; Jia X; Ballantyne CM; Hoogeveen RC
Eur J Prev Cardiol; 2022 Mar; 29(2):e53-e64. PubMed ID: 33580780
[TBL] [Abstract][Full Text] [Related]
2. Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease.
Saeed A; Feofanova EV; Yu B; Sun W; Virani SS; Nambi V; Coresh J; Guild CS; Boerwinkle E; Ballantyne CM; Hoogeveen RC
J Am Coll Cardiol; 2018 Jul; 72(2):156-169. PubMed ID: 29976289
[TBL] [Abstract][Full Text] [Related]
3. ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
Chan DC; Watts GF
Curr Opin Lipidol; 2024 Jun; 35(3):101-109. PubMed ID: 38372218
[TBL] [Abstract][Full Text] [Related]
4. ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis.
Mohamed F; Mansfield BS; Raal FJ
Curr Atheroscler Rep; 2022 Dec; 24(12):959-967. PubMed ID: 36367663
[TBL] [Abstract][Full Text] [Related]
5. ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.
Akoumianakis I; Zvintzou E; Kypreos K; Filippatos TD
Curr Atheroscler Rep; 2021 Mar; 23(5):20. PubMed ID: 33694000
[TBL] [Abstract][Full Text] [Related]
6. Prognostic utility of triglyceride-rich lipoprotein-related markers in patients with coronary artery disease.
Cao YX; Zhang HW; Jin JL; Liu HH; Zhang Y; Xu RX; Gao Y; Guo YL; Zhu CG; Hua Q; Li YF; Santos RD; Wu NQ; Li JJ
J Lipid Res; 2020 Sep; 61(9):1254-1262. PubMed ID: 32641433
[TBL] [Abstract][Full Text] [Related]
7. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?
Reeskamp LF; Tromp TR; Stroes ESG
Curr Opin Lipidol; 2020 Jun; 31(3):140-146. PubMed ID: 32324598
[TBL] [Abstract][Full Text] [Related]
8. Relationship between Serum Angiopoietin-like Proteins 3 and 8 and Atherogenic Lipid Biomarkers in Non-Diabetic Adults Depends on Gender and Obesity.
Murawska K; Krintus M; Kuligowska-Prusinska M; Szternel L; Stefanska A; Sypniewska G
Nutrients; 2021 Nov; 13(12):. PubMed ID: 34959891
[TBL] [Abstract][Full Text] [Related]
9. Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk.
Gobeil É; Bourgault J; Mitchell PL; Houessou U; Gagnon E; Girard A; Paulin A; Manikpurage HD; Côté V; Couture C; Marceau S; Bossé Y; Thériault S; Mathieu P; Vohl MC; Tchernof A; Arsenault BJ
Eur Heart J; 2024 Mar; 45(9):707-721. PubMed ID: 38243829
[TBL] [Abstract][Full Text] [Related]
10. Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis.
Hernandez P; Passi N; Modarressi T; Kulkarni V; Soni M; Burke F; Bajaj A; Soffer D
Curr Atheroscler Rep; 2021 Sep; 23(11):72. PubMed ID: 34515873
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
[TBL] [Abstract][Full Text] [Related]
12. Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions.
Hussain A; Ballantyne CM; Saeed A; Virani SS
Curr Atheroscler Rep; 2020 Jun; 22(7):25. PubMed ID: 32494924
[TBL] [Abstract][Full Text] [Related]
13. New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3.
Kim JY; Kim NH
J Lipid Atheroscler; 2023 Jan; 12(1):23-36. PubMed ID: 36761060
[TBL] [Abstract][Full Text] [Related]
14. A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?
Ward NC; Chan DC; Watts GF
BioDrugs; 2022 Mar; 36(2):121-135. PubMed ID: 35286660
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.
Ruscica M; Zimetti F; Adorni MP; Sirtori CR; Lupo MG; Ferri N
Pharmacol Res; 2020 Mar; 153():104653. PubMed ID: 31931117
[TBL] [Abstract][Full Text] [Related]
16. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
17. Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention.
Quispe R; Sweeney T; Varma B; Agarwala A; Michos ED
Curr Atheroscler Rep; 2022 Oct; 24(10):767-778. PubMed ID: 35895246
[TBL] [Abstract][Full Text] [Related]
18. Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia.
Nurmohamed NS; Dallinga-Thie GM; Stroes ESG
Expert Rev Cardiovasc Ther; 2020 Jun; 18(6):355-361. PubMed ID: 32511037
[TBL] [Abstract][Full Text] [Related]
19. Association of triglyceride-rich lipoproteins-related markers and low-density lipoprotein heterogeneity with cardiovascular risk: effectiveness of polyacrylamide-gel electrophoresis as a method of determining low-density lipoprotein particle size.
Tani S; Matsumoto M; Nagao K; Hirayama A
J Cardiol; 2014 Jan; 63(1):60-8. PubMed ID: 24016623
[TBL] [Abstract][Full Text] [Related]
20. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol.
Xu YX; Redon V; Yu H; Querbes W; Pirruccello J; Liebow A; Deik A; Trindade K; Wang X; Musunuru K; Clish CB; Cowan C; Fizgerald K; Rader D; Kathiresan S
Atherosclerosis; 2018 Jan; 268():196-206. PubMed ID: 29183623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
